JNHA - The Journal of Nutrition, Health and Aging

, Volume 13, Issue 9, pp 808–812 | Cite as

Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer’s disease: ADAS-cog subscale results from the Alphase study

  • D. Saumier
  • Anh DuongEmail author
  • D. Haine
  • D. Garceau
  • J. Sampalis
ADAS-Cog Subscale Results from the Alphase Study



Tramiprosate (homotaurine, ALZHEMED™) was recently investigated for its efficacy, safety and disease-modification effects in a Phase III clinical study in mild to moderate Alzheimer’s disease (AD) patients (the Alphase study). The primary cognitive endpoint measure of that study was the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog). To characterize potential cognitive benefits of tramiprosate, the present study describes exploratory analyses performed on scores obtained from the specific ADAS-cog subscales in order to determine whether specific domains of cognition may be differentially affected by tramiprosate, which would not have been evident from the measure’s total score.


Multi-center, double-blind, randomized, placebo-controlled study.


67 investigative sites in the United States and Canada.


A total of 1,052 patients were randomized. Interventions: Patients were randomized to receive twice a day Placebo (n=353), tramiprosate 100 mg (n=352) and tramiprosate 150 mg (n=347).


ADAS-cog assessments were conducted every three months over the 78-week study period. Exploratory analyses were performed by comparing ADAS-cog subscale scores between Placebo and each active treatment arm at each visit.


The findings of this analysis revealed statistically significant differences or statistical trends in favour of tramiprosate on six ADAS-cog subscales, namely Following Commands, Language Comprehension, Ideational Praxis, Object Naming, Remembering Test Instructions, and Spoken Language Ability. Differences in favor of Placebo were only observed on the Constructional Praxis subscale.


This exploratory analysis suggests that tramiprosate may have some benefit on memory, language and praxis skills in mild to moderate AD individuals. Future clinical studies of tramiprosate should include specialized neuropsychological tests to validate its effects within these cognitive domains.


Memantine Language Comprehension Object Naming Ideational Praxis Homotaurine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gervais F, Paquette J, Morissette C, et al. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 2007; 28(4):537–547.CrossRefGoogle Scholar
  2. 2.
    Krzywkowski P, Sebastiani G, Williams S, et al. Tramiprosate Prevents Amyloid Beta-induced Inhibition of Long-term Potentiation in Rat Hippocampal Slices. 8th International Conference AD/PD, Salzburg, Austria, March 14–18. 2007.Google Scholar
  3. 3.
    Azzi M, Morissette C, Fallon L, et al. Involvement of both GABA-dependent and — independent pathways in tramiprosate neuroprotective effects against amyloid-beta toxicity. 8th International Conference AD/PD, Salzburg, Austria, March 14–18. 2007.Google Scholar
  4. 4.
    Aisen PS, Saumier D, Briand R, et al. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology, 2006; 67:1757–1763.CrossRefPubMedGoogle Scholar
  5. 5.
    Aisen PS, Gauthier S, Ferris SH et al. Tramiprosate in Mild-to-Moderate Alzheimer’s Disease: a Randomized, Double-blind, Placebo-controlled, Multi-centre Study (the Alphase Study). Submitted.Google Scholar
  6. 6.
    Mohs RC, Cohen L. Alzheimer’s Disease Assessment Scale (ADAS). Psychopharmacol Bull 1988; 24: 627–628.PubMedGoogle Scholar
  7. 7.
    Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412–2414.PubMedGoogle Scholar
  8. 8.
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition, Text Revision. Washington, DC, American Psychiatric Association 2000; 154–158.Google Scholar
  9. 9.
    McKhann G, Drachman D, Folskein M, et al. Clinical Diagnosis of Alzheimer’s Disease: Report of the NINCDS-ADRDA Word Group under the Auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34, 939–944.PubMedGoogle Scholar
  10. 10.
    Folstein MF, Folstein SE and McHugh PR. (1975). “Mini-Mental State” A Practical Method for Grading the Cognitive State of Patients for the Clinician. J Psychiat Res 12, 189–198.CrossRefPubMedGoogle Scholar
  11. 11.
    Gauthier S. Aisen PS, Ferris SH. et al. Effect of tramiprosate in patients with mild-tomoderate Alzheimer’s Disease: Exploratory analyses of the MRI sub-group of the Alphase study. J Nutr Health Aging. 2009; 13(6):550–557.CrossRefGoogle Scholar
  12. 12.
    Nilsson LG.Memory function in normal aging. Acta Neurol Scand Suppl. 2003; 179:7–13.Google Scholar
  13. 13.
    Buckner RL. Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate. Neuron 2004; 44(1):195–208.CrossRefGoogle Scholar
  14. 14.
    Joubert S, Barbeau E, Joanette Y, Ska B. In: Gauthier S, editor. Clinical Diagnosis and Management of Alzheimer’s Disease (3rd edition). Abingdon, Oxon (UK): Informa Healthcare, pp. 165–176. 2007.Google Scholar
  15. 15.
    Rainville C, Caza N, Belleville S, et al. In: Gauthier S, editor. Clinical Diagnosis and Management of Alzheimer’s Disease, 3rd edition. Abingdon, Oxon (UK): Informa Healthcare, pp. 67–80. 2007.Google Scholar
  16. 16.
    Zimmerman ME, Brickman AM, Paul RH, et al. The relationship between frontal gray matter volume and cognition varies across the healthy adult lifespan. Am J Geriatr Psychiatry 2006; 14(10):823–833.CrossRefGoogle Scholar
  17. 17.
    Buckner RL. Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate. Neuron 2004; 44(1):195–208.CrossRefGoogle Scholar
  18. 18.
    Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A 42 in humans. Ann Neurol 2006; 59(3):512–519.CrossRefGoogle Scholar
  19. 19.
    Forsberg A, Engler H, Almkvist O, et al. (2007). PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008; 29(10):1456–1465.CrossRefGoogle Scholar
  20. 20.
    Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid B-peptide in the brain and cognitive decline. JAMA 2000; 283: 1571–1577.CrossRefPubMedGoogle Scholar
  21. 21.
    Kuchibhotla KV, Lattarulo CR, Hyman BT, et al. BJ. Synchronous Hyperactivity and Intercellular Calcium Waves in Astrocytes in Alzheimer Mice. Science. 2009;323(5918):1211–1215.CrossRefPubMedGoogle Scholar
  22. 22.
    Möhler H, Fritschy JM, Vogt K, et al. Pathophysiology and pharmacology of GABA(A) receptors. In: Holsboer F; Ströhle A, editors. Anxiety and Anxiolytic Drugs. New York (NY): Springer-Verlag (Handbook of Experimental Pharmacology, vol. 169): 225–247. 2005.CrossRefGoogle Scholar

Copyright information

© Serdi and Springer Verlag France 2009

Authors and Affiliations

  • D. Saumier
    • 1
  • Anh Duong
    • 2
    Email author
  • D. Haine
    • 2
  • D. Garceau
    • 3
  • J. Sampalis
    • 2
    • 4
  1. 1.Department of Neurology and NeurosurgeryMcGill UniversityMontrealCanada
  2. 2.JSS Medical ResearchWestmountCanada
  3. 3.OVOS Natural Health Inc.LavalCanada
  4. 4.Division of Clinical EpidemiologyMcGill University, Research Institute of the McGill University Health Centre, Royal Victoria HospitalMontrealCanada

Personalised recommendations